The latest quarterly earnings report for McKesson Corporation is scheduled for Wednesday, May 6th, with a consensus estimated EPS of $11.56.
McKesson Corporation, with a current price of $836, has seen a price increase of $7.7 (0.93%) from the previous close. The trading volume stands at $177,700, which is 22% above the average.
In the most recent quarterly earnings report on Tuesday, February 3rd, McKesson Corporation reported a consensus EPS of $9.31.
McKesson Corporation has a forward dividend yield of 0.392% and a dividend per share of 82 cents MRQ, with a year-over-year increase of 15.0376 cents.
The company's cash flow indicates a free cash flow of $1.12 billion, debt repayment of $1.20 billion, and a net change in cash of -$1 billion.
McKesson Corporation reported a net income of $1.19 billion, translating to an EPS of $9.63. The company achieved a gross profit of $3.69 billion on revenues of $106.16 billion.
Key ratios for McKesson Corporation include a net profit margin of 1.12%, return on assets of 1.41, and a price-to-earnings ratio of 21.3.
With total assets of $84.19 billion and total liabilities of $84.29 billion, McKesson Corporation maintains a net debt position of $5.67 billion.
This comprehensive overview provides insights into McKesson Corporation's financial performance and upcoming earnings expectations.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.